<DOC>
	<DOC>NCT00824187</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).</brief_summary>
	<brief_title>YAZ Premenstrual Dysphoric Disorder (PMDD) in China</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Chinese women of reproductive age 1845 years (inclusive) with a diagnosis of Premenstrual Dysphoric Disorder (PMDD) Any formal psychotherapeutic counselling within 1 month before the screening visit (Visit 1) or used medication for Premenstrual Syndrome (PMS) or Premenstrual Dysphoric Disorder (PMDD) including, but not limited to hormones, bromocriptine, GnRH agonists, vitamin B6 (&gt;100 mg), calcium supplements (&gt; 1500 mg/day), anxiolytics and antidepressants during the 3 month period prior to Visit 1 Use of sleeping medication (including melatonin) for more than 3 days per month. Pregnancy or less than 3 menstrual cycles since delivery, abortion or lactation before start of treatment Obesity (body mass index or BMI &gt; 30 kg/m2) Hypersensitivity to any ingredient of the study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Premenstrual Dysphoric Disorder ( PMDD)</keyword>
	<keyword>Oral contraceptive</keyword>
</DOC>